Skip to main content

What is the difference between Truxima and Rituxan?

Medically reviewed by Kristianne Hannemann, PharmD. Last updated on March 25, 2025.

Official Answer by Drugs.com

Truxima (rituximab-abbs) is a biosimilar to Rituxan (rituximab). While both drugs are CD20-directed cytolytic antibodies used to treat non-Hodgkin’s lymphoma (NHL), Rituxan has additional FDA-approved indications beyond NHL.

What Is a Biosimilar?

Biosimilars are highly similar to an already-approved biological product and have no clinically meaningful differences in terms of safety, purity, and potency.

FDA-Approved Uses: Truxima vs. Rituxan

Truxima and Rituxan belong to the class of drugs called CD20-directed cytolytic antibodies.

Both medications are approved for the treatment of adult patients with non-Hodgkin’s lymphoma (NHL):

Rituxan is additionally indicated for several other medical conditions in adults patients, including:

It is also approved to treat children 6 years and older with mature B-cell NHL and mature B-cell acute leukemia.

For more information, see What Are Biosimilars? Top Facts You May Not Know

Related questions

References

Read next

What is a chemotherapy regimen?

A chemotherapy (chemo) regimen consists of anti-cancer medicines you receive over a set period of time (usually over several cycles). Chemo regimens, such as R-CHOP, are often abbreviated by using the first letter of the drug names. For example, R-CHOP is an abbreviation for a 5-drug chemotherapy regimen used to treat non-Hodgkin’s lymphoma, a type of blood cancer.

Continue reading

What is the success rate of Rituxan (rituximab) in rheumatoid arthritis?

Treatment with Rituxan (rituximab) successfully improves patient outcomes in patients with rheumatoid arthritis including reducing symptoms, reducing levels of fatigue and disability, and increasing health-related quality of life. It also slows the progression of structural damage in joints. Continue reading

What causes infusion reactions to rituximab?

Rituximab infusion reactions are caused primarily by cytokine release in the body. Cytokines are immune system proteins in the body that help to fight infections but can cause an inflammatory response. Infusion reactions may cause hives, itching, shortness of breath, chest pain or dizziness and are a very common side effect of treatment with rituximab (Rituxan). Continue reading

See also:

Related medical questions

Drug information

Related support groups